...Haitao Zhang; Xin Yang; Fangfang Zheng; Suhua Wan; Yingying Xu Introduction: The aim of this study was to compare the changes in serum concentrations of vascular endothelial growth factor (VEGF)-A and B after intravitreal injection of ranibizumab (IVR) or conbercept (IVC) for retinopathy...

...Marko M. Popovic; Tom Sheidow; Jason Baker; Peter J. Kertes Introduction: The Canadian Treat-and-Extend Analysis Trial with Ranibizumab (CANTREAT) was a 2-year, multicentred, randomized clinical trial to evaluate treat-and-extend (T&E) relative to monthly administration of ranibizumab...

... ). Aflibercept Bevacizumab Dexamethasone Ranibizumab Triamcinolone acetonide Retinal vein occlusions (RVOs) are one of the leading causes of vision loss in people above the age of 40 [ 1 ]. Macular edema (ME) secondary to RVO is typically treated with anti-vascular endothelial growth factor (anti...

... intravitreal injections of ranibizumab (loading phase [LP]) in patients affected by polypoidal choroidal vasculopathy (PCV). Methods: A total of 30 eyes of 30 PCV patients and 30 eyes of 30 healthy subjects as the control group were enrolled in this prospective study. The best-corrected visual acuity (BCVA...

...) or anti-VEGF (aflibercept, 2 mg/0.05 mL, Bayer© or ranibizumab, 0.5 mg/0.05 mL, Novartis©) were administered intravitreally through the pars plana using the original implanting devices. The data collected were best-corrected visual acuity (BCVA) using an ETDRS chart (converted to a decimal scale, as used...

... with syringes that were prefilled by GMP pharmacies or the manufacturers was significantly lower than that following injections which were self-drawn by the physician (0.019% vs. 0.055%, p < 0.0001). For ranibizumab, risk of endophthalmitis decreased since it became available in a prefilled syringe (0.054...

... from any ideas, methods, instructions or products referred to in the content or advertisements. Age-related macular degeneration Real-life study Macular degeneration Optical coherence tomography Anti-VEGF Vascular endothelial growth factor Ranibizumab Aflibercept Neovascular age...

...Manuel Falcão Purpose: Evaluation of the impact of the injection frequency of ranibizumab on best-corrected visual acuity (BCVA) outcomes in patients with diabetic macular edema (DME). Methods: A meta-analysis of randomized controlled trials (RCTs) and real-world studies was performed to quantify...

...Maria-Magdalena Guichard; Géraldine Peters; Cengiz Tuerksever; Christian Pruente; Katja Hatz Purpose: To analyze the efficacy and outcome predictors of SD-OCT (spectral-domain optical coherence tomography)-driven ranibizumab treatment in patients with choroidal neovascularization due to myopia...

... and functional outcomes between patients receiving ranibizumab or aflibercept. Results: Seventy-five eyes of 61 patients met the inclusion criteria and had follow-up for 1 year. Baseline BCVA and CRT were 68.1 ± 13.2 letters and 424 ± 135 µm, retrospectively. After 1 year, there was a significant mean gain...

.... In this study, we investigate the effects of ranibizumab (Lucentis®), bevacizumab (Avastin®), and aflibercept (Eylea®) on primary human retinal pigment epithelial (hRPE) cells in vitro. Methods: hRPE cells were prepared from donor eyes and cultured under standard culture conditions. Scleral fibroblasts also...

...Shashikant Sharma; Mujtaba A. Khan; Alok Chaturvedi; RE-ENACT Study Investigators Group Background: This subgroup analysis of the RE-ENACT study evaluates the effectiveness of Razumab® (the world’s first biosimilar of ranibizumab by Intas Pharmaceuticals Ltd.) in Indian patients with retinal vein...

...Sabit Kimyon; Alper Mete Purpose: To investigate the effects of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP) affecting zone 1. Methods: Files of the patients who received intravitreal bevacizumab (IVB) or ranibizumab (IVR) treatment for ROP affecting zone...

...Cláudia Farinha; Amélia Martins; Arminda Neves; Raquel Soares; Miguel Ruão; Mário Ornelas; Pedro Neves; Filipa Gomes Rodrigues; Constança Coelho; Rufino Silva Purpose: The purpose of this study was to evaluate the 2-year outcome of ranibizumab for diabetic macular oedema (DME) in the real-life...

...Pedro Gil; João Gil; Nuno Oliveira; Inês Laíns; Eduardo Nery Rossi Camilo; Cristina Fonseca; Miguel Raimundo; Maria da Luz Cachulo; Rufino Silva Purpose: To investigate the influence of the vitreoretinal interface on the outcomes of different ranibizumab regimens for exudative age-related macular...

...Marco R. Pastore; Vittorio Capuano; Elsa Bruyère; Alexandra Miere; Eleonora Corbelli; Lea Querques; Daniele Tognetto; Francesco Bandello; Giuseppe Querques; Eric H. Souied Purpose: The aim of this study was to evaluate the 9-year outcome of ranibizumab monotherapy for myopic choroidal...

...Atsushi Sugiyama; Yoichi Sakurada; Shigeru Honda; Akiko Miki; Wataru Matsumiya; Seigo Yoneyama; Wataru Kikushima; Hiroyuki Iijima Purpose: The aim of this study was to investigate the clinical implications of required retreatment after 3-monthly intravitreal ranibizumab (IVR) injections followed...

...Shafi Balal; Jonathan Than; Sharmila Tekriwal; Aires Lobo Purpose: Evaluation of outcomes in retinal vein occlusions (RVOs) for: (1) multiple repeat dexamethasone (DEX) injections and (2) conversion from DEX to ranibizumab. Methods: We conducted a retrospective study evaluating outcomes of multiple...

...Cristina Calvo-González; Juan Reche-Frutos; José Ignacio Fernández-Vigo; Federico Sáenz-Francés; Cristina Fernández-Pérez; Julian García-Feijóo Purpose: To compare two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization. Methods: A total...

... with neovascular and dry AMD were enrolled. Eligible neovascular AMD patients received 2 intravitreal loading doses of either ranibizumab 0.5 mg or bevacizumab 1.25 mg at 4-week intervals and were subsequently followed every 4 weeks and treated according to a pro re nata regime for up to 1 year. Patients with dry...